IDWeek 2021: Clinical Impact of New Data*

Download All
September 29 - October 3, 2021; Virtual
Apply new and emerging management options for vaccine-preventable diseases presented at IDWeek 2021 featuring expert faculty analysis in a webinar, podcast, downloadable slideset, and commentary.
Paul G. Auwaerter, MD
Martin C. Mahoney, MD, PhD

IDWeek 2021: Clinical Impact of New Data on Vaccine-Preventable Diseases

Studies at IDWeek 2021 show that pneumococcal vaccines with increased serotype valency are safe and efficacious in both children and adults. Here is my take on how these studies could affect my practice and the current vaccination guidelines.

Paul G. Auwaerter, MD Released: November 19, 2021

Listen to expert insights from Martin C. Mahoney, MD, PhD, on new data for vaccine-preventable diseases presented at the IDWeek meeting, including pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.

Martin C. Mahoney, MD, PhD Released: December 6, 2021

In this downloadable slideset, CCO’s expert faculty summarizes important studies from IDWeek 2021, including new data on vaccines for pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.

Martin C. Mahoney, MD, PhD Released: November 3, 2021

Hear unique insights from expert faculty on important studies from IDWeek 2021, including new data on vaccines for pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.

Martin C. Mahoney, MD, PhD Released: November 11, 2021
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings